WO2007135774A1 - 生薬配合経口液剤組成物 - Google Patents
生薬配合経口液剤組成物 Download PDFInfo
- Publication number
- WO2007135774A1 WO2007135774A1 PCT/JP2007/000535 JP2007000535W WO2007135774A1 WO 2007135774 A1 WO2007135774 A1 WO 2007135774A1 JP 2007000535 W JP2007000535 W JP 2007000535W WO 2007135774 A1 WO2007135774 A1 WO 2007135774A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fatty acid
- acid ester
- content
- component
- oral liquid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to a herbal medicine-containing oral solution composition having good stability under low temperature conditions.
- Patent Document 1 describes that a liquid composition containing polyfluorolin becomes stable for a long time when blended with polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, and polyethylene glycol fatty acid ester. Has been.
- Patent Document 2 describes that a combination of a polyglycerin fatty acid ester, a polyoxyethylene-based nonionic surfactant and an oil component is good for solubilizing ginsenosides.
- a polyglycerin fatty acid ester, a polyoxyethylene nonionic surfactant and an oil component are blended into a crude drug extract, and the blending amount of the polyoxyethylene nonionic surfactant is A solubilized liquid composition having 1/6 parts by weight to 1 part by weight of glycerin fatty acid ester is described.
- Patent Document 4 describes blending polyoxychethylene hardened castor oil and polyoxychethylene polyoxypropylene condensate with a crude drug extract.
- Patent Document 1 Japanese Patent Laid-Open No. 2 00 _ 2 4 7 8 90
- Patent Document 2 Japanese Patent Laid-Open No. 2 0 0 2 _ 1 9 3 8 2 5
- Patent Document 3 Japanese Patent Laid-Open No. 2 0 0 2-1 2 8 7 0 3
- Patent Document 4 Japanese Patent Publication No. 5-9 4 0 8 Disclosure of the invention
- the storage stability of the herbal medicine component-containing liquid preparation differs greatly depending on the herbal ingredients to be blended, as described in Patent Documents 1 and 2, and particularly the stabilization of the oral liquid medicine containing a plurality of herbal medicine ingredients. It is difficult.
- the flow through winter and cold regions can be as low as 5 ° C, so it is hoped to develop a stable oral solution that will not precipitate or become cloudy even when stored for long periods under low temperature conditions. It was rare.
- the present inventor has examined the stability of a liquid preparation containing a crude drug component.
- sucrose fatty acid ester, the monoglycerin fatty acid ester, and glycyrrhizic acid or a salt thereof are combined, the temperature becomes high. It was found that a stable oral solution was obtained without precipitation for about 1 month not only under conditions but also at low temperatures.
- the present invention provides the following components (A) to (F):
- the oral liquid composition of the present invention is stable without causing precipitation and cloudiness for a long period of time under low temperature conditions. Therefore, the oral liquid composition of the present invention can be distributed stably in winter or in cold regions.
- the herbal medicine component (A) used in the present invention is one or more selected from carrots, ginseng, taisaw, peony, toki, and keihi.
- ginseng root extract of Panax ginseng is used as carrot.
- ginger a ginger rhizome extract is used.
- the extract of jujube fruit from the family Aceraceae is used.
- the peonies the extract of the roots of Peonies is used.
- As the touki an extract of the roots of the celery family is used.
- gehi an extract of the bark of the cinnamon cassia of the camphor family is used.
- the form of the extract is not particularly limited, and examples thereof include a dry extract, a stream extract, a soft extract, etc. In the present invention, it is preferable to use a stream extract or a soft extract.
- extraction solvents for obtaining these extracts include water and ethanol.
- These herbal ingredients (A) can be blended in the oral liquid composition of the present invention in one kind or two or more kinds. It is preferable to mix herbal medicine ingredients, and further, it is preferable to mix ginseng and cypress, and if necessary, mix one or more selected from taiso, peony, toki and keihi.
- the total content of these crude drug ingredients (A) as the value of the crude drug equivalent is not particularly limited, but from the viewpoint of pharmacological effects, it is 5 to 5 in the oral solution composition of the present invention. 2 5% by weight, further 1 0-2 5 wt%, and particularly preferably 1 5 to 2 5 mass 0 / o.
- sucrose fatty acid ester used in the present invention (B) sucrose C 14 _C 18 fatty acid ester is preferable.
- Examples of commercially available sucrose fatty acid esters (B) include DK ester SS (Daiichi Kogyo).
- the relative mass ratio of the content of the crude drug component (A) and the sucrose fatty acid ester (B) in the oral liquid composition of the present invention is not particularly limited, but from the viewpoint of preventing the precipitation of the crude drug component,
- the content of the sucrose fatty acid ester (B) is in the range of 0.00004 to 0.02, where the content of the crude drug component (A) in the oral liquid composition of the present invention is 1 It is preferable to be inside.
- the content of the sucrose fatty acid ester (B) is not particularly limited, but from the viewpoint of preventing precipitation of the crude drug component, 0.001 to 0.00 in the oral liquid composition of the present invention. It is preferably 1 mass 0 / o, more preferably 0.005 to 0.04 mass%, particularly preferably 0.0 1 to 0.02 mass%.
- monoglycerin fatty acid ester (C) used in the present invention monoglycerol C 14 _C 18 fatty acid ester is preferable.
- examples of commercially available monoglycerin fatty acid ester (C) include Poem M-1100 (manufactured by Riken Vitamin).
- the relative mass ratio of the content of the crude drug component (A) and the monoglycerin fatty acid ester (C) in the oral liquid composition of the present invention is not particularly limited, but from the viewpoint of preventing precipitation of the crude drug component,
- the content of the monoglycerin fatty acid ester (C) is within the range of 0.00004 to 0.02 when the content of the crude drug component (A) in the oral liquid composition of the invention is 1 (concentration value of the crude drug) It is preferable that
- the content of the monoglycerin fatty acid ester (C) is not particularly limited, but from the viewpoint of preventing precipitation of crude drug components, 0.001 to 0.1 mass in the oral liquid composition of the present invention. %, further 0.005 to 0.04 mass 0 / o, in particular 0.0 1 to 0.02 mass 0 / o and is the is not preferable.
- the glycyrrhizic acid or a salt thereof (D) used in the present invention includes pharmaceutically acceptable salts in addition to daricyrrhizic acid itself.
- the salts include alkali metal salts, Alkaline earth metal salts, ammonium salts, etc. Can be mentioned.
- Examples of glycyrrhizic acid or a salt thereof (D) include, for example, dipotassium dallicyl ritinate, monoammonium glycyrrhizinate, disodium glycyrrhizinate, and trisodium glycyrrhizinate.
- nitric acid glycyrrhizinate is preferable from the viewpoint of the precipitation preventing effect.
- examples of commercially available products of glycyrrhizic acid or its salt (D) include glycyrrhizic acid dipotassium (manufactured by Alps Chemicals) and the like.
- the relative mass ratio of the content of the herbal medicine component (A) and the glycyrrhizic acid or its salt (D) in the oral liquid composition of the present invention is not particularly limited, but from the viewpoint of preventing precipitation of the herbal medicine component.
- the content of the crude drug component (A) in the oral liquid composition of the present invention is defined as 1, the content of glycyrrhizic acid or a salt thereof (D) is from 0.00004 to 0.02. It is preferable to be within the range. Further, the content of glycyrrhizic acid or a salt thereof (D) is not particularly limited, but from the viewpoint of preventing precipitation of crude drug components, 0.001 to 0.001 in the oral liquid composition of the present invention. It is preferably 1 mass 0 / o, more preferably 0.005 to 0.04 mass%, particularly preferably 0.01 to 0.02 mass%.
- Examples of the polyoxyethylene hydrogenated castor oil (E) used in the present invention include hydrogenated castor oil having a polyoxyethylene average addition mole number of 5 to 120, and particularly a polyoxyethylene average addition mole number of 20 to 80 hydrogenated castor oil is preferred.
- Examples of commercially available products of polyoxyethylene hydrogenated castor oil include HCO-60 (manufactured by Nippon Surfactant), EMALEX HC-60 (manufactured by Nippon Margyon), and the like.
- the relative mass ratio of the content of the crude drug component (A) and the polyoxyethylene hydrogenated castor oil (E) in the oral liquid composition of the present invention is not particularly limited, but from the viewpoint of preventing precipitation of the crude drug component.
- the content of the polyoxyethylene hydrogenated castor oil (E) in the oral liquid composition of the present invention is defined as 0. It is preferable to be within the range of 0.2.
- the content of polyoxyethylene hydrogenated castor oil (E) is not particularly limited, but from the viewpoint of preventing precipitation of crude drug components, 0.001 to 1 mass in the oral liquid composition of the present invention. %, Further from 0.005 to 0.5 mass 0 / o, is preferably especially 0.01 to 0.1 mass 0 / o.
- Examples of the polyvinyl pyrrolidone (F) used in the present invention include polyvinyl pyrrolidone having an average molecular weight of 10,000, 2,000 to 2,000, 000, and polyvinyl pyrrolidone having an average molecular weight of 20,000 to 50,000 is particularly preferable.
- Examples of commercially available products of polyvinyl pyrrolidone include Kollidon 25 (manufactured by BAS F Japan) and Eyefact K-30 (manufactured by Daiichi Kogyo Seiyaku).
- the relative mass ratio of the content of the crude drug component (A) and the polyvinylpyrrolidone (F) in the oral liquid composition of the present invention is not particularly limited, but from the viewpoint of preventing the occurrence of white turbidity, the oral liquid composition of the present invention It is preferable that the content of polyvinylpyrrolidone (F) is within the range of 0.0004 to 0.4, where the content of the crude drug component (A) in the product (the value of the crude drug equivalent) is 1.
- polyvinylpyrrolidone (F) is not particularly limited, but from the viewpoint of preventing the occurrence of cloudiness, 0.01 to 2% by mass, and further 0.05 to It is preferably 1 mass 0 / o, especially 0.1 to 0.5 mass%.
- the oral liquid composition of the present invention not only the crude drug component (A), but also sucrose fatty acid ester (B), monoglycerin fatty acid ester (C), and glycyrrhizic acid or a salt thereof (D), Further, by blending polyoxyethylene hydrogenated castor oil (E) and polyvinylpyrrolidone (F) in combination, a long-term storage stabilizing effect under low temperature conditions can be obtained.
- the relative mass ratio of the content of each of the above components in the oral liquid composition of the present invention is not particularly limited, but from the viewpoint of preventing precipitation of crude drug components and preventing clouding, the oral liquid composition of the present invention Content of sucrose fatty acid ester (B), monoglycerin fatty acid ester (C), and glycyrrhizic acid or its salt (D) when the content of crude drug component (A) In the range of 0.00004 to 0.02, the content of polyoxyethylene hydrogenated castor oil (E) in the range of 0.00004 to 0.2, and the content of polyvinylpyrrolidone (F) in the range of 0.004 to 0.4 It is preferable to be inside.
- the oral liquid composition of the present invention may further contain other medicinal ingredients, sweeteners, pH adjusters, antioxidants, colorants, fragrances, flavoring agents, preservatives, water and the like.
- the other medicinal ingredients are aloe, wikiweed, turquoise, nyak, engosaku, age, woogi, ousei, onji, garana, kukosi, jiou, ⁇ chu, amarogentin, ougon, oubak, gaul Cascara Sagrada, Katsuko, Cascarinoki, Forced sword grass, Carocon, Kikiyo, Pheasant, Kiyonin, Kihada, Cuco, Kuzin, Gay guy, Kakemeishi, Gengoshi, Gentiana, Gennoshouko, Kojin, Kobushi, Kopoku, Gopoku Trash, colompo, konslango, sico, sangishi, saffron, sansho, sanzukon, jio
- Sweeteners include sucrose, lactose, fructose, glucose, honey, sorbitol, and multi! ⁇ L, Erysri I ⁇ l, Xyliri I ⁇ l, trehalose, saccharin and its salts, aspartame, acesulfame K, stevia extract and the like.
- Examples of the pH adjusting agent include those capable of adjusting the pH to 4 to 7, particularly 5 to 6.
- antioxidants examples include ascorbic acid and its salt, erythorbic acid and its salt, edetic acid and its salt, sodium bisulfite, gallic acid propylene and the like.
- colorant examples include tar pigment, iron sesquioxide, and caramel.
- fragrance examples include apple flavor.
- corrigent examples include citrate and its salt, L_glutamic acid and its salt, I_menthol and the like.
- preservatives examples include benzoic acid and its salts, parabens and the like.
- the oral liquid composition of the present invention can be produced by mixing the aforementioned raw materials into an aqueous solution form.
- the liquid composition obtained by the present invention can be used as an oral liquid composition for nutritional tonic, for example, due to the pharmacological action of a crude drug or the like to be blended.
- ginseng extract carrot extract ⁇ made in Japan powder
- peonies extract pepper extract _A ⁇ made in Japan powder
- toki extract toki extract
- 5mg 50 Omg of raw drug equivalent
- Shoyo Extract Shokiyo-style extract ⁇ made in Japan powder
- 0.5mL 50 Omg of crude drug equivalent
- Taisou Extract Taisou Extract
- OmL Drug substance equivalent value 100 Omg
- Gehi extract Geihe style Eki ⁇ Made in Japan powder
- Sucrose fatty acid ester DK ester SS ⁇ Daiichi Kogyo Co., Ltd. 5.
- Omg monoglycerin fatty acid ester (Poem M-1 00 'manufactured by Riken Vitamin)
- Omg dipotassium glycyrrhizinate (dipotassium dallicyllithate' Alps Yakuhin)
- Omg 3 Omg citrate was added and dissolved by stirring. To this, sodium citrate was added to adjust the pH to 5.5, and an appropriate amount of purified water (room temperature) was added to produce an oral solution with a total volume of 30 mL (specific gravity: 1.05).
- Comparative Example 1 According to the formulation in Table 1, an oral solution was prepared in the same manner as in Reference Example 1 except that no monoglycerin fatty acid ester was added.
- an oral solution was prepared in the same manner as in Reference Example 1 except that sucrose fatty acid ester was not added.
- an oral solution was prepared in the same manner as in Reference Example 1 except that glycyrrhizic acid bismuth was not added.
- an oral solution was prepared in the same manner as in Reference Example 1 except that polyethylene glycol fatty acid ester was added instead of monodallyserine fatty acid ester and sucrose fatty acid ester.
- Comparative Examples 1 and 2 precipitation was observed even at 60 ° C for 1 month. Furthermore, in an oral liquid preparation (Comparative Example 4) in which polyethylene glycol fatty acid ester was blended with sucrose fatty acid ester and monodallyserine fatty acid ester, precipitation was observed at 5 ° C for 1 month.
- ginseng extract carrot extract ⁇ made in Japan powder
- peonies extract pepper extract _A ⁇ made in Japan powder
- toki extract toki extract
- 5mg 50 Omg of raw drug equivalent
- Shoyo Extract Shokiyo-style extract ⁇ made in Japan powder
- 0.5mL 50 Omg of crude drug equivalent
- Taisou Extract Taisou Extract
- OmL Drug substance equivalent value 100 Omg
- Gehi extract Gaihe style Eki ⁇ Made in Japan powder
- DK ester SS Sucrose fatty acid ester
- Omg monoglycerin fatty acid ester (Poem M-1 00 'manufactured by Riken Vitamin)
- Omg dipotassium glycyrrhizinate (dipotassium dallicyllithate' Alps Yakuhin) 5.0 mg Polyoxyethylene hydrogenated castor oil (HCO- 60 ⁇ Japan Sir factor cement) 20.
- Omg polyvinylpyrrolidone (coli Don 25 ⁇ BAS F Ja pan) 1 00.
- the Kuen acid 3 Omg added and stirred to dissolve.
- Sodium citrate was added to adjust the pH to 5.5, and an appropriate amount of purified water (room temperature) was added to produce an oral solution with a total volume of 3 OmL (specific gravity: 1.05).
- Comparative Example 5 According to the formulation shown in Table 2, an oral solution was prepared in the same manner as in Example 1 except that polyvinylpyrrolidone was not added.
- an oral solution was prepared in the same manner as in Example 1 except that polyvinylpyrrolidone and polyoxyethylene hydrogenated castor oil were not added.
- Example 1 and Comparative Examples 5 and 6 were stored in the dark for 1 month and 2 months at 5 ° C, the appearance and stability of each oral solution with respect to precipitation or cloudiness was visually observed. Evaluated. Appearance stability is indicated by ⁇ for the case where precipitation did not occur and X for the case where precipitation occurred. Concerning white turbidity, the clear one is marked with ⁇ , and the white turbidity is marked with X. The results are shown in Table 2.
- polyvinylpyrrolidone into a herbal medicine blended oral liquid such as ginseng and peonies blended with sucrose fatty acid ester, monoglycerin fatty acid ester, glycyrrhizin di-nitrous acid and polyoxyethylene hydrogenated castor oil (Example 1) After 2 months at 5 ° C, no precipitate or cloudiness was observed, and an oral solution formulation with good appearance stability could be obtained.
- a herbal medicine blended oral liquid such as ginseng and peonies blended with sucrose fatty acid ester, monoglycerin fatty acid ester, glycyrrhizin di-nitrous acid and polyoxyethylene hydrogenated castor oil
- sucrose fatty acid ester monoglycerin fatty acid ester, glycyrrhizic acid or its salt, polyoxyethylene hydrogenated castor oil and polyvinylpyrrolidone
- oral liquids containing herbal medicines such as carrots and peonies. It was possible to obtain a crude drug-containing oral solution having good appearance stability under low-temperature conditions for a long period of time.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008516559A JPWO2007135774A1 (ja) | 2006-05-23 | 2007-05-21 | 生薬配合経口液剤組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006142567 | 2006-05-23 | ||
JP2006-142567 | 2006-05-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007135774A1 true WO2007135774A1 (ja) | 2007-11-29 |
Family
ID=38723088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/000535 WO2007135774A1 (ja) | 2006-05-23 | 2007-05-21 | 生薬配合経口液剤組成物 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2007135774A1 (ja) |
KR (1) | KR20090010162A (ja) |
WO (1) | WO2007135774A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010041702A1 (ja) * | 2008-10-08 | 2010-04-15 | 株式会社 ポッカコーポレーション | 抗鳥インフルエンザウイルス剤及び抗鳥インフルエンザウイルス剤含有製品 |
JP2011256166A (ja) * | 2010-05-14 | 2011-12-22 | Kowa Co | 安定な水性液剤 |
JP2012012336A (ja) * | 2010-06-30 | 2012-01-19 | Rohto Pharmaceutical Co Ltd | 内服用固形製剤 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08333265A (ja) * | 1995-06-07 | 1996-12-17 | Taisho Pharmaceut Co Ltd | イブプロフェン懸濁液剤 |
JP2002119242A (ja) * | 2000-10-13 | 2002-04-23 | Kinjirushi Wasabi Kk | 耐熱性および水分散性に優れた香味製品 |
JP2002128703A (ja) * | 2000-10-25 | 2002-05-09 | Taisho Pharmaceut Co Ltd | 生薬配合可溶化液体組成物 |
JP2003310212A (ja) * | 2002-04-23 | 2003-11-05 | Maruzen Pharmaceut Co Ltd | 水分散性又は水溶解性のバナバ葉抽出物組成物 |
JP2004091392A (ja) * | 2002-08-30 | 2004-03-25 | Biomedeikusu:Kk | 水分散用水難溶性成分含有組成物および飲料 |
JP4073411B2 (ja) * | 2004-03-11 | 2008-04-09 | シャープ株式会社 | 通信機器及び該通信機器の低消費電力モード選択方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57189657A (en) * | 1981-05-16 | 1982-11-22 | Mitsubishi Chem Ind Ltd | Preparation of soya milk for drinking |
JPS6051104A (ja) * | 1983-08-30 | 1985-03-22 | Ajinomoto Co Inc | ビタミンe含有水性液剤 |
JPS61268627A (ja) * | 1985-05-23 | 1986-11-28 | Koukandou:Kk | 水性液剤の製法 |
JP2000312572A (ja) * | 1999-04-30 | 2000-11-14 | Dai Ichi Kogyo Seiyaku Co Ltd | 蛋白飲料の沈殿防止剤 |
-
2007
- 2007-05-21 JP JP2008516559A patent/JPWO2007135774A1/ja active Pending
- 2007-05-21 WO PCT/JP2007/000535 patent/WO2007135774A1/ja active Application Filing
- 2007-05-21 KR KR1020087023437A patent/KR20090010162A/ko not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08333265A (ja) * | 1995-06-07 | 1996-12-17 | Taisho Pharmaceut Co Ltd | イブプロフェン懸濁液剤 |
JP2002119242A (ja) * | 2000-10-13 | 2002-04-23 | Kinjirushi Wasabi Kk | 耐熱性および水分散性に優れた香味製品 |
JP2002128703A (ja) * | 2000-10-25 | 2002-05-09 | Taisho Pharmaceut Co Ltd | 生薬配合可溶化液体組成物 |
JP2003310212A (ja) * | 2002-04-23 | 2003-11-05 | Maruzen Pharmaceut Co Ltd | 水分散性又は水溶解性のバナバ葉抽出物組成物 |
JP2004091392A (ja) * | 2002-08-30 | 2004-03-25 | Biomedeikusu:Kk | 水分散用水難溶性成分含有組成物および飲料 |
JP4073411B2 (ja) * | 2004-03-11 | 2008-04-09 | シャープ株式会社 | 通信機器及び該通信機器の低消費電力モード選択方法 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010041702A1 (ja) * | 2008-10-08 | 2010-04-15 | 株式会社 ポッカコーポレーション | 抗鳥インフルエンザウイルス剤及び抗鳥インフルエンザウイルス剤含有製品 |
US8603548B2 (en) | 2008-10-08 | 2013-12-10 | Pokka Corporation | Anti-avian influenza virus agent, and product containing anti-avian influenza virus agent |
JP5558360B2 (ja) * | 2008-10-08 | 2014-07-23 | ポッカサッポロフード&ビバレッジ株式会社 | 抗鳥インフルエンザウイルス剤及びその使用 |
JP2011256166A (ja) * | 2010-05-14 | 2011-12-22 | Kowa Co | 安定な水性液剤 |
JP2012012336A (ja) * | 2010-06-30 | 2012-01-19 | Rohto Pharmaceutical Co Ltd | 内服用固形製剤 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2007135774A1 (ja) | 2009-10-01 |
KR20090010162A (ko) | 2009-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schmidt et al. | Toxicological evaluation of a chicory root extract | |
Matthias et al. | Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion | |
AU2018202482A1 (en) | Racecadotril liquid compositions | |
WO2014002599A1 (ja) | 生薬等含有医薬組成物 | |
US9827231B2 (en) | Liquid pharmaceutical composition | |
ES2643716T3 (es) | Formulaciones novedosas que comprenden extractos herbáceos | |
CN101505769A (zh) | 用于治疗口腔疾病的草药组合物 | |
AU2018360383A1 (en) | Extract of orthosiphon stamineus, formulations, and uses thereof | |
JP2002003365A (ja) | 銅クロロフィリン塩含有液剤組成物 | |
ES2633467T3 (es) | Formulaciones estables | |
KR101523586B1 (ko) | 전립선 비대증 예방 또는 치료용 약학적 조성물 및 이의 제조방법 | |
JP4889948B2 (ja) | 服用感に優れた内服液剤 | |
US20220143126A1 (en) | Synergistic combination of phytoactives | |
WO2007135774A1 (ja) | 生薬配合経口液剤組成物 | |
Mansouri et al. | The effects of pomegranate extract on normal adult rat kidney: A stereological study | |
AU2014235724A1 (en) | Racecadotril liquid compositions | |
CN104873461A (zh) | 一种拉莫三嗪口服溶液的制备方法 | |
Elkomy et al. | Renal protective effect of cardamom against nephrotoxicity induced by gentamicin in rats | |
JP5083492B2 (ja) | 内服用液剤 | |
Kagalkar et al. | Development and evaluation of herbal fast dissolving tablets of Tectona grandis Linn | |
Sheth et al. | DISINTEGRATING TABLET OF LORNOXICAM | |
ES2905407T3 (es) | Composiciones que contienen curcumina con biodisponibilidad mejorada | |
WO2007125653A1 (ja) | 生薬配合経口液剤組成物 | |
KR100818091B1 (ko) | 자동 미셀화 약물송달시스템을 이용한 경구용플라보노리그난의 약학적 조성물 | |
JP2013095670A (ja) | 炭酸含有内用液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07737191 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2008516559 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087023437 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07737191 Country of ref document: EP Kind code of ref document: A1 |